Medriva covers Actinium 225: A Promising Isotope for Cancer Treatment.
Scientists at Los Angeles National Laboratory (LANL) are increasing the production of the isotope actinium 225, a promising advancement in the treatment of prostate cancer and other malignancies. This isotope emits strong radiation that can damage cancer cells without causing significant harm to healthy ones. The production of actinium 225 was previously dependent on the slow decay of thorium, but now, significant efforts are being made to accelerate this process in order to meet the potential demand for cancer treatments.
Read the coverage HERE
